DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Manas Mishra - 2 Joe Biden - 1 Jonathan Ernst - 1 Biden - 1 Joe Biden’s - 1 Januvia - 1 Xarelto - 1
Top related locs:
Bengaluru Tampa , Florida U.S Amgen's Jardiance Germany Washington United States
Top related orgs:
Pfizer - 2 NYSE Arca Pharmaceutical - 2 Thomson - 2 Social Security - 1 University of Tampa - 1 REUTERS - 1 U.S - 1 Bristol Myers Squibb - 1

Search resuls for: "NYSE Arca Pharmaceutical"


5 mentions found


☆ Blood thinners, diabetes meds among first 10 drugs for US price negotiations
  + stars: | 2023-08-29 | by ( Patrick Wingrove Michael Erman | Patrick Wingrove | Michael Erman | ) www.reuters.com   time to read: +5 min
He said that once implemented, the prices on negotiated drugs will decrease for up to 9 million seniors who currently pay as much as $6,497 in out-of-pocket costs per year for these prescriptions. This kicks off the negotiation process for the 10 drugs whose new prices will go into effect in 2026. U.S. laws had prohibited Medicare from negotiating pharmaceutical prices as part of its prescription drug program that began about 20 years ago. CMS Director Dr. Meena Seshamani said Medicare plans to use a review process to make sure insurance companies keep clinically appropriate access to negotiated drugs. Two analysts said they expect the negotiated prices to move beyond Medicare and affect commercial markets for these drugs by 2026, when they come into effect.
Persons: Joe Biden, Jonathan Ernst, Biden, Joe Biden’s, Januvia, Xarelto, Johnson, Boehringer Ingelheim, Eli Lilly's, Jardiance, Mohit Bansal, Entresto, Eli Lilly, Merck, Bristol Myers, Giovanni Caforio, Caforio, enrollees, Meena Seshamani, Stelara, Amgen, Evan Seigerman, Patrick Wingrove, Mike Erman, Manas Mishra, Nandita Bose, Caroline Humer, Bill Berkrot Organizations: Social Security, University of Tampa, REUTERS, U.S, Bristol Myers Squibb, Pfizer, Merck, Co's, Johnson, Novo Nordisk, NYSE Arca Pharmaceutical, U.S . Centers, Medicare, Medicaid Services, Reuters Graphics Wells, Novartis, AstraZeneca, Bristol, J, U.S . Department of Health, Human Services, BMO Capital, Thomson Locations: Tampa , Florida, U.S, Amgen's, Jardiance, Germany, Bengaluru, Washington
☆ Pfizer scraps one weight loss drug in race to develop Ozempic rival
  + stars: | 2023-06-26 | by ( Michael Erman Manas Mishra | Michael Erman | Manas Mishra | ) www.reuters.com   time to read: +3 min
Pfizer CEO Albert Bourla has said an obesity pill could eventually be a $10-billion-a-year product for Pfizer. Truist Securities analyst Robyn Karnauskas said Lilly is now ahead in the race for a once-a-day obesity pill. Pfizer said last month that danuglipron helped patients lose weight on par with Novo Nordisk's (NOVOb.CO) Ozempic in a mid-stage study that tested it in patients with Type 2 diabetes. None of the patients in the lotiglipron trials reported liver-related symptoms or side effects, there was no evidence of liver failure and none required treatment, Pfizer said. Liver enzyme elevations observed in lotiglipron trials have not been seen in patients enrolled in danuglipron trials, the company added.
Persons: Albert Bourla, Eli Lilly, LLY.N, Robyn Karnauskas, Lilly, Pfizer, danuglipron, Manas Mishra, Leroy Leo, Michael Erman, Pooja Desai, Jason Neely, Deepa Babington Organizations: Pfizer Inc, Pfizer, NYSE Arca Pharmaceutical, Truist Securities, Novo Nordisk's, Thomson Locations: United States, Bengaluru, New Jersey
☆ Why Biotech Is Poised for a Recovery This Year
  + stars: | 2023-01-17 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
The SPDR S&P Biotech ETF is up 5.9% and the NYSE Arca Pharmaceutical Index is down marginally at the start of the year. The drug industry is now divided between the haves and the have-nots. That wide gap in mood was in stark relief as thousands of industry professionals descended upon San Francisco last week for JPMorgan ‘s big healthcare conference. On one side were giddy pharma executives with plenty of access to cash and their stocks trading near record highs. On the other side, there were cash-strapped small biotech bosses, speaking of layoffs and suspended clinical trials.
☆ Bank of America just added these biotech stocks to its list of first-quarter picks
  + stars: | 2023-01-09 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
BofA has added a number of biotechnology stocks — a sector that is hot on Wall Street right now – to its list of top picks for the first quarter. The bank identified the biotech stocks, as well as some medical technology companies, as part of its thematic investing picks, on themes it says are related to a "transforming world." BofA listed the stocks under themes such as ageing, obesity and pandemic. The bank added biotech firm BioNTech , as well as medical equipment company ResMed , to its list under this theme. The bank added medical technology firm Silk Road Medical , along with biotech firms Cerevel and Denali , to its list of stocks to play this theme.
☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
  + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.
0 next >>
Total: 5